<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39421085</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>In Silico Evaluation of HIV Protease and RNA Polymerase Inhibitors as Potential COVID-19 Therapeutics.</ArticleTitle><Pagination><StartPage>e69576</StartPage><MedlinePgn>e69576</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e69576</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.69576</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 coronavirus, also known as the acute respiratory syndrome coronavirus, emerged as a significant global health concern. First identified in Wuhan, China, in December 2019, the virus rapidly spread to over 187 countries due to its high transmissibility. Until an effective treatment or vaccine is developed, preventive measures remain the only mandatory strategy to curb person-to-person transmission.</AbstractText><AbstractText Label="AIMS AND OBJECTIVES" NlmCategory="OBJECTIVE">The study aimed to explore potential therapeutic options for COVID-19 by repurposing existing drugs. Specifically, the objective was to evaluate a library of clinically approved or investigational antiviral compounds through docking studies to identify candidates with high binding affinity to COVID-19 proteins.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The study employed molecular docking techniques using the Maestro interface (Schrodinger Suite, LLC, NY) to assess the interaction of selected compounds with various COVID-19 protein targets. A total of 15 compounds were analyzed for their binding potential to multiple forms of the virus's proteins.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The docking studies revealed that several compounds, particularly HIV protease inhibitors and RNA-dependent RNA polymerase inhibitors, demonstrated strong binding affinities to key COVID-19 enzymes. These interactions suggest their potential as therapeutic candidates for COVID-19 treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings from this drug repurposing study highlight the potential of certain existing antiviral agents in the treatment of COVID-19. The identified compounds could serve as promising candidates for further investigation in the ongoing battle against the coronavirus pandemic.</AbstractText><CopyrightInformation>Copyright © 2024, Devaraji et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Devaraji</LastName><ForeName>Mahalakshmi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai, IND.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravikumar</LastName><ForeName>Lokeshvar</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences, Chennai, IND.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral drugs</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">dock score</Keyword><Keyword MajorTopicYN="N">molecular docking</Keyword><Keyword MajorTopicYN="N">sars-cov-2</Keyword></KeywordList><CoiStatement>Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39421085</ArticleId><ArticleId IdType="pmc">PMC11483341</ArticleId><ArticleId IdType="doi">10.7759/cureus.69576</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Early estimates of updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023-January 2024. Link-Gelles R, Ciesla AA, Mak J, et al. MMWR Morb Mortal Wkly Rep. 2024;73:77–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10843065</ArticleId><ArticleId IdType="pubmed">38300853</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus disease (COVID-19): a scoping review. Lv M, Luo X, Estill J, et al. Euro Surveill. 2020;25</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175649</ArticleId><ArticleId IdType="pubmed">32317050</ArticleId></ArticleIdList></Reference><Reference><Citation>Post-COVID syndrome: an insight on its pathogenesis. Maltezou HC, Pavli A, Tsakris A. Vaccines (Basel) 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8151752</ArticleId><ArticleId IdType="pubmed">34066007</ArticleId></ArticleIdList></Reference><Reference><Citation>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Rothan HA, Byrareddy SN. J Autoimmun. 2020;109:102433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127067</ArticleId><ArticleId IdType="pubmed">32113704</ArticleId></ArticleIdList></Reference><Reference><Citation>Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. Liu C, Zhou Q, Li Y, et al. ACS Cent Sci. 2020;6:315–331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10467574</ArticleId><ArticleId IdType="pubmed">32226821</ArticleId></ArticleIdList></Reference><Reference><Citation>Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MU, Khan K. J Travel Med. 2020;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7107534</ArticleId><ArticleId IdType="pubmed">31943059</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus disease 2019-COVID-19. Dhama K, Khan S, Tiwari R, et al. Clin Microbiol Rev. 2020;33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405836</ArticleId><ArticleId IdType="pubmed">32580969</ArticleId></ArticleIdList></Reference><Reference><Citation>Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Elfiky A. Life Sci. 2020;248:11747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089605</ArticleId><ArticleId IdType="pubmed">32119961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Wrapp D, Wang N, Corbett KS, et al. Science. 2020;367:1260–1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host−virus interaction, and proposed neurotropic mechanisms. Baig AM, Khaleeq A, Ali U, Syeda H. ACS Chem Neurosci. 2020;11:995–998.</Citation><ArticleIdList><ArticleId IdType="pubmed">32167747</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) Sohrabi C, Alsafi Z, O'Neill N, et al. Int J Surg. 2020;76:71–76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105032</ArticleId><ArticleId IdType="pubmed">32112977</ArticleId></ArticleIdList></Reference><Reference><Citation>A commentary on "World Health Organization declares global emergency: a review of the 2019 novel Coronavirus (COVID-19)". Shah SG, Farrow A. Int J Surg. 2020;76:128–129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128929</ArticleId><ArticleId IdType="pubmed">32169574</ArticleId></ArticleIdList></Reference><Reference><Citation>Approved antiviral drugs over the past 50 years. De Clercq E, Li G. Clin Microbiol Rev. 2016;29:695–747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical trials with antiviral drugs against COVID-19: some progress and many shattered hopes. Brüssow H. Environ Microbiol. 2021;23:6364–6376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652531</ArticleId><ArticleId IdType="pubmed">34519154</ArticleId></ArticleIdList></Reference><Reference><Citation>Novel ligand-based docking; molecular dynamic simulations; and absorption, distribution, metabolism, and excretion approach to analyzing potential acetylcholinesterase inhibitors for Alzheimer's disease. Vijayakumar S, Manogar P, Prabhu S, Sanjeevkumar Singh RA. J Pharm Anal. 2018;8:413–420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6308024</ArticleId><ArticleId IdType="pubmed">30595949</ArticleId></ArticleIdList></Reference><Reference><Citation>Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents. Modi P, Patel S, Chhabria M. Bioorg Chem. 2019;87:240–251.</Citation><ArticleIdList><ArticleId IdType="pubmed">30908967</ArticleId></ArticleIdList></Reference><Reference><Citation>A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β. Pradeep H, Rajanikant GK. Mol Divers. 2012;16:553–562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7089308</ArticleId><ArticleId IdType="pubmed">22918724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryo-electron microscopy structure of porcine delta coronavirus spike protein in the prefusion state. Shang J, Zheng Y, Yang Y, et al. J Virol. 2018;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790952</ArticleId><ArticleId IdType="pubmed">29070693</ArticleId></ArticleIdList></Reference><Reference><Citation>Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Amporndanai K, Meng X, Shang W, et al. Nat Commun. 2021;12:3061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8144557</ArticleId><ArticleId IdType="pubmed">34031399</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Kim Y, Jedrzejczak R, Maltseva NI, et al. Protein Sci. 2020;29:1596–1605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264519</ArticleId><ArticleId IdType="pubmed">32304108</ArticleId></ArticleIdList></Reference><Reference><Citation>Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Lv Z, Deng YQ, Ye Q, et al. Science. 2020;369:1505–1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402622</ArticleId><ArticleId IdType="pubmed">32703908</ArticleId></ArticleIdList></Reference><Reference><Citation>Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: an in silico and in vitro study. Sinha S, Patel S, Athar M, Vora J, Chhabria MT, Jha PC, Shrivastava N. Int J Biol Macromol. 2019;140:454–468.</Citation><ArticleIdList><ArticleId IdType="pubmed">31404596</ArticleId></ArticleIdList></Reference><Reference><Citation>Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL. J Med Chem. 2004;47:1750–1759.</Citation><ArticleIdList><ArticleId IdType="pubmed">15027866</ArticleId></ArticleIdList></Reference><Reference><Citation>Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach. Jasuja H, Chadha N, Kaur M, Silakari O. Mol Divers. 2014;18:253–267.</Citation><ArticleIdList><ArticleId IdType="pubmed">24415188</ArticleId></ArticleIdList></Reference><Reference><Citation>Merits and pitfalls of conventional and covalent docking in identifying new hydroxyl aryl aldehyde like compounds as human IRE1 inhibitors. Carlesso A, Chintha C, Gorman AM, Samali A, Eriksson LA. Sci Rep. 2019;9:3407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6399222</ArticleId><ArticleId IdType="pubmed">30833722</ArticleId></ArticleIdList></Reference><Reference><Citation>Reverse screening methods to search for the protein targets of chemopreventive compounds. Huang H, Zhang G, Zhou Y, et al. Front Chem. 2018;6:138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5954125</ArticleId><ArticleId IdType="pubmed">29868550</ArticleId></ArticleIdList></Reference><Reference><Citation>Identification of potential CRAC channel inhibitors: pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach. Bhuvaneshwari S, Sankaranarayanan K. SAR QSAR Environ Res. 2019;30:81–108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30773908</ArticleId></ArticleIdList></Reference><Reference><Citation>Direct-acting antiviral agents for hepatitis C virus infection-from drug discovery to successful implementation in clinical practice. Dietz C, Maasoumy B. Viruses. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9231290</ArticleId><ArticleId IdType="pubmed">35746796</ArticleId></ArticleIdList></Reference><Reference><Citation>A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. Cao B, Wang Y, Wen D, et al. N Engl J Med. 2020;382:1787–1799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Wen W, Chen C, Tang J, et al. Ann Med. 2022;54:516–523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 antiviral therapy. Tao K, Tzou PL, Nouhin J, Bonilla H, Jagannathan P, Shafer RW. Clin Microbiol Rev. 2021;34:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8404831</ArticleId><ArticleId IdType="pubmed">34319150</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug treatment of COVID-19 infection. Lui G, Guaraldi G. Curr Opin Pulm Med. 2023;29:174–183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10090306</ArticleId><ArticleId IdType="pubmed">36917228</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. Elfiky AA. J Biomol Struct Dyn. 2021;39:3204–3212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222627</ArticleId><ArticleId IdType="pubmed">32338164</ArticleId></ArticleIdList></Reference><Reference><Citation>Structural basis of the potential binding mechanism of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase. Zhang L, Zhou R. J Phys Chem B. 2020;124:6955–6962.</Citation><ArticleIdList><ArticleId IdType="pubmed">32521159</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs. Jiang M, Väisänen E, Kolehmainen P, et al. Vaccine. 2023;41:3813–3823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10126225</ArticleId><ArticleId IdType="pubmed">37142461</ArticleId></ArticleIdList></Reference><Reference><Citation>ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Gentile I, Borgia F, Buonomo AR, Zappulo E, Castaldo G, Borgia G. Curr Med Chem. 2014;21:3261–3270.</Citation><ArticleIdList><ArticleId IdType="pubmed">25005190</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>